Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,230.71
(
-0.16%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
78,427.99
(
1.04%
)
News Focus
News Focus
Post# of 517600
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

georgejjl

Send PM Follow Ignore
Followers 147
Posts 26201
Boards Moderated 0
Alias Born 04/08/2004

georgejjl

Re: runncoach post# 379571

Sunday, 10/23/2022 12:15:21 PM

Sunday, October 23, 2022 12:15:21 PM

Post# of 517600
runncoach, READ THE FOLLOWING:

The inclusion criteria for the Phase 2a Blarcamesine Alzheimer's disease treatment trial originally allowed the use of donepezil, BUT that was removed during the progression of the trial.

If a participant is taking donepezil (allowed acetylcholinesterase inhibitor) then the medication must be maintained on a stable dose regimen for at least 90 days prior to screening evaluations. Donepezil dose is limited to 20 mg/day (with 10mg/d being the maximal recommended daily dose in Australia).

GOD bless,
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News